Evidence Synthesis Program (ESP) Coordinating Center, VA Portland Health Care System, Portland, Oregon.
J Head Trauma Rehabil. 2020 May/Jun;35(3):198-208. doi: 10.1097/HTR.0000000000000549.
To systematically review the prevalence of dementia in Veterans versus civilians and the association between previous traumatic brain injuries (TBIs) and the risk and timing of dementia onset in Veterans.
We systematically searched MEDLINE, PsycINFO, and Cochrane Central Register of Controlled Trials from database inception to October 2018. One reviewer assessed articles for inclusion, evaluated study quality, graded strength of evidence, and extracted data, with second reviewer checking.
Forty articles were included, among which 10 presented the best evidence. Evidence suggests that dementia rates are likely similar between Veterans and civilians (10.7% vs 8.8%-11.6%, respectively). Dementia prevalence is likely higher in those with TBI (6%-16%) than in those without (3%-10%), with a possible dose-response relationship between the two. There may also be an association between TBI and early-onset dementia, although this evidence has important limitations. No studies evaluated whether dementia prevalence varied on the basis of combat deployment history or era of conflict.
Dementia prevalence is likely similar in Veteran and civilian populations, and the risk of dementia is likely increased by TBI. To inform development of screening, prevention, and rehabilitation efforts, research is still needed addressing the mechanism of association and timing of dementia onset.
PROSPERO; CRD42018107926.
系统地回顾退伍军人与平民中痴呆症的患病率,以及既往创伤性脑损伤(TBI)与退伍军人痴呆症发病风险和发病时间的关系。
我们系统地检索了 MEDLINE、PsycINFO 和 Cochrane 对照试验中心注册库从建库起至 2018 年 10 月的数据。一名评审员评估纳入的文章,评估研究质量,对证据强度进行分级,并提取数据,由第二名评审员进行核对。
共纳入 40 篇文章,其中 10 篇提供了最佳证据。有证据表明,退伍军人和平民中痴呆症的发病率可能相似(分别为 10.7%和 8.8%-11.6%)。TBI 患者(6%-16%)的痴呆症患病率可能高于无 TBI 者(3%-10%),两者之间可能存在剂量-反应关系。TBI 与早发性痴呆之间也可能存在关联,但该证据存在重要局限性。没有研究评估痴呆症的患病率是否基于战斗部署史或冲突时代而有所不同。
退伍军人和平民人群中的痴呆症发病率可能相似,TBI 可能增加痴呆症的风险。为了制定筛查、预防和康复措施,仍需要研究痴呆症发病机制和发病时间的关联。
PROSPERO;CRD42018107926。